𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Maintenance Therapy With Certolizumab Pegol After Induction Therapy for Active Crohn's Disease: 6-Month Results

✍ Scribed by Sandborn, William J. ;Schreiber, Stefan ;Feagan, Brian G. ;Rutgeerts, Paul J. ;Younes, Ziad H. ;Sen, David L. ;D'Haens, Geert R.

Book ID
122296512
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
463 KB
Volume
140
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of certolizumab pego
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
✍ Alain M. Schoepfer; Stephan R. Vavricka; Janek Binek; Christian Felley; Martin G πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 142 KB

Background: Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based